Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder

References

• Haylen BT, De Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. doi:10.1002/nau.2079819941278
   PubMed Web of Science ®Google Scholar
• Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95. doi:10.1016/j.eururo.2013.08.03124007713
   PubMed Web of Science ®Google Scholar
• Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Managed Care Pharm. 2014;20(2):130–140. doi:10.18553/jmcp.2014.20.2.130
   Google Scholar
• Andersson KE, Cardozo L, Cruz F, Lee KS, Sahai A, Wein AJ. Pharmacological treatment of urinary incontinence In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence 6th edition. 2017:805–957.
   Google Scholar
• Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood–brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(4):259–273. doi:10.2165/11597530-000000000-0000022390261
   PubMed Web of Science ®Google Scholar
• Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27(1):127–138. doi:10.1016/j.clinthera.2005.01.00615763613
   PubMed Web of Science ®Google Scholar
• Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235–246. doi:10.1111/j.1365-2125.2011.03961.x21392072
   PubMed Web of Science ®Google Scholar
• Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23(4):248–252. doi:10.1007/s00345-005-0507-316096831
   PubMed Web of Science ®Google Scholar
• Wolters Kluwer Pharma Solutions. Source Lx Managed Care Database. 2010.
   Google Scholar
• Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–14.
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–1483. doi:10.1111/j.1532-5415.2011.03491.x21707557
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–610. doi:10.2174/13892001179650452721495970
   PubMed Web of Science ®Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167–174. doi:10.1111/j.1755-5949.2011.00248.x22070184
   PubMed Web of Science ®Google Scholar
• Hustveit O. Interaction between opioid and muscarinic receptors in the guineapig ileum preparation: a mathematical model. Pharmacol Toxicol. 1996;78(3):167–173. doi:10.1111/j.1600-0773.1996.tb00199.x8882350
   PubMedGoogle Scholar
• Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2019;Dec:1–7.
   Google Scholar
• Villalba-Moreno AM, Alfaro-Lara ER, Pérez-Guerrero MC, Nieto-Martín MD, Santos-Ramos B. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr. 2016;62:1–8. doi:10.1016/j.archger.2015.10.00226518612
   PubMed Web of Science ®Google Scholar
• Lozano-Ortega G, Johnston KM, Cheung A, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020;87:103885. doi:10.1016/j.archger.2019.05.01031155228
   PubMed Web of Science ®Google Scholar
• Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain – how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151–159. doi:10.1111/bcpt.1214024112192
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745–755. doi:10.1093/ageing/afv07726104505
   PubMed Web of Science ®Google Scholar
• Fick DM, Semla TP, Beizer J. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246. doi:10.1111/jgs.1370226446832
   PubMed Web of Science ®Google Scholar
• O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–218. doi:10.1093/ageing/afu14525324330
   PubMed Web of Science ®Google Scholar
• http://www.agingbraincare.org/tools/abc-anticholinergic-cognitive-burden-scale. Accessed 8 13, 2020.
   Google Scholar
• Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75(2):152–159. doi:10.1212/WNL.0b013e3181e7f2ab20625168
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–615. doi:10.1093/ageing/afu09625038833
   PubMed Web of Science ®Google Scholar
• Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):235–238. doi:10.1002/ana.1063912891676
   PubMed Web of Science ®Google Scholar
• Roher AE, Kuo YM, Potter PE, et al. Cortical cholinergic denervation elicits vascular Aβ deposition. Ann N Y Acad Sci. 2000;903(1):366–373. doi:10.1111/j.1749-6632.2000.tb06388.x10818527
   PubMed Web of Science ®Google Scholar
• Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–732. doi:10.1001/jamaneurol.2016.058027088965
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. doi:10.1001/jamainternmed.2014.766325621434
   PubMed Web of Science ®Google Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;25(361):k1315. doi:10.1136/bmj.k1315
   Web of Science ®Google Scholar
• Campbell NL, Lane KA, Gao S, Boustani MA, Unverzagt F. Anticholinergics influence transition from normal cognition to mild cognitive impairment in older adults in primary care. Pharmacotherapy. 2018;38(5):511–519. doi:10.1002/phar.210629600808
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dementia. 2007;3(3):186–191. doi:10.1016/j.jalz.2007.04.381
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence: Urinary incontinence and pelvic organ prolapse in women: management.NICE Guideline [NG123].2019.
   Google Scholar
• Ju R, Garrett J, Wu JM. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. Int Urogynecol J. 2014;25(4):479–484. doi:10.1007/s00192-013-2246-024158462
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–1300. doi:10.1111/j.1742-1241.2010.02433.x20561092
   PubMed Web of Science ®Google Scholar
• Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004;5(6):423–426. doi:10.1007/s11934-004-0064-015541209
   PubMedGoogle Scholar
• Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol. 1994;47(4):337–343. doi:10.1007/BF01911657875185
   PubMed Web of Science ®Google Scholar
• Geller EJ, Crane AK, Wells EC, et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig. 2012;32(10):697–705. doi:10.1007/BF3261923
   PubMed Web of Science ®Google Scholar
• Geller EJ, Dumond JB, Bowling JM, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118–123. doi:10.1097/SPV.000000000000037428067745
   PubMed Web of Science ®Google Scholar
• Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. doi:10.1136/bmjopen-2018-021889
   PubMed Web of Science ®Google Scholar
• Wagg AS, Foley S, Peters J, Nazir J, Kool‐Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK general practice prescription database. Int J Clin Pract. 2017;71(10):e12996. doi:10.1111/ijcp.12996
   Web of Science ®Google Scholar
• Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay‐Smith EJC. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Sys Rev. 2012. doi:10.1002/14651858.CD005429.pub2
   Web of Science ®Google Scholar
• Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621–638. doi:10.1185/03007995.2016.114980626828974
   PubMed Web of Science ®Google Scholar
• Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a Phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–220. doi:10.1016/j.eururo.2019.10.00231733990
   PubMed Web of Science ®Google Scholar
• Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: moCA results from a Phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):1. doi:10.1186/s12877-020-1474-7
   Web of Science ®Google Scholar
• Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus. 2017;3(6):629–638. doi:10.1016/j.euf.2017.08.00828916436
   PubMedGoogle Scholar
• Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord. 2018;1(57):22–26. doi:10.1016/j.parkreldis.2018.07.005
   Web of Science ®Google Scholar
• Wagg A. Anticholinergics for overactive bladder in frail and medically complex older people: the case for. Drugs Aging. 2018;35(9):777–780. doi:10.1007/s40266-018-0577-830097909
   PubMed Web of Science ®Google Scholar
• Hashim H, Al Mousa R. Management of fluid intake in patients with overactive bladder. Curr Urol Rep. 2009;10(6):428–433. doi:10.1007/s11934-009-0068-x19863853
   PubMedGoogle Scholar
• Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102(1):62–66. doi:10.1111/j.1464-410X.2008.07463.x18284414
   PubMed Web of Science ®Google Scholar
• Lee JG, Wein AJ, Levin RM. The effect of caffeine on the contractile response of the rabbit urinary bladder to field stimulation. Gen Pharmacol. 1993;24(4):1007–1011. doi:10.1016/0306-3623(93)90180-68224728
   PubMedGoogle Scholar
• Jura YH, Townsend MK, Curhan GC, Resnick NM, Grodstein F. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol. 2011;185(5):1775–1780. doi:10.1016/j.juro.2011.01.00321420114
   PubMed Web of Science ®Google Scholar
• Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scan. 1984;63(3):257–260. doi:10.3109/00016348409155509
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405.23076892
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004 Oct 1; 83(10):892–897. Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA. Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy. Int Urogynecol J. 2019;18:1–6.
   Google Scholar
• Palmer C, Farhan B, Nguyen N, Ghoniem G. Clinical outcomes of percutaneous tibial nerve stimulation in elderly patients with overactive bladder. Arab J Urology. 2019;17(1):10–13. doi:10.1080/2090598X.2019.1590032
   PubMed Web of Science ®Google Scholar
• Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature. Eur Urol. 2018;73(3):406–418. doi:10.1016/j.eururo.2017.11.00229336927
   PubMed Web of Science ®Google Scholar
• Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge-incontinent population. Am J Obstet Gynecol. 2002;187(6):1462–1465. doi:10.1067/mob.2002.13000412501047
   PubMed Web of Science ®Google Scholar
• White WM, Mobley III JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Sacral nerve stimulation for refractory overactive bladder in the elderly population. J Urol. 2009;182(4):1449–1452. doi:10.1016/j.juro.2009.06.04919683295
   PubMed Web of Science ®Google Scholar
• Faris AE, Gill BC, Pizarro-Berdichevsky J, et al. Impact of age and comorbidities on use of sacral neuromodulation. J Urol. 2017;198(1):161–166. doi:10.1016/j.juro.2017.02.02028192077
   PubMed Web of Science ®Google Scholar
• Pratt TS, Suskind AM. Management of overactive bladder in older women. Curr Urol Rep. 2018;19(11):92. doi:10.1007/s11934-018-0845-530203368
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhou X, Zong H, Yan H, Zhang Y. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta‐analysis. Neurourol Urodyn. 2015;34(5):413–419. doi:10.1002/nau.2259824676791
   PubMed Web of Science ®Google Scholar
• Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017;28(6):845–850. doi:10.1007/s00192-016-3212-427889830
   PubMed Web of Science ®Google Scholar
• Cottenden A, Fader M, Beeckman BB, et al. Management using continence products. In:Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence 6th edition 2017:2303–2402.
   Google Scholar
• American Urological Association. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: An AUA/SUFU Guideline (2019). American Urological Association; 2019.
   Google Scholar
• Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615–626. doi:10.1517/1474033090326079019747069
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–326. doi:10.1016/j.eururo.2006.03.05716687205
   PubMed Web of Science ®Google Scholar
• Wagg A, Arumi D, Herschorn S, et al. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing. 2017;46(4):620–626. doi:10.1093/ageing/afw25228057620
   PubMed Web of Science ®Google Scholar
• Oelke M, Murgas S, Schneider T, Heßdörfer E. Influence of propiverine ER 30 mg once daily on cognitive function in elderly female and male patients with overactive bladder: a non-interventional study to assess real life data. Neurourol Urodyn. 2013;32(6):800–802.
   Web of Science ®Google Scholar
• Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects. InProc 36th Meeting Int Continence Soc. 2006;25(6):P087.
   Google Scholar
• Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74–81. doi:10.1016/j.eururo.2013.01.00223332882
   PubMed Web of Science ®Google Scholar
• Woodford HJ. Anticholinergic drugs for overactive bladder in frail older patients: the case against. Drugs Aging. 2018;35(9):773–776. doi:10.1007/s40266-018-0575-x30097908
   PubMed Web of Science ®Google Scholar
• Samuelsson E, Odeberg J, Stenzelius K, et al. Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: a systematic review. Geriatr Gerontol Int. 2015;15(5):521–534. doi:10.1111/ggi.1245125656412
   PubMed Web of Science ®Google Scholar
• Triantafylidis LK, Clemons JS, Peron EP, Roefaro J, Zimmerman KM. Brain over bladder: a systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging. 2018;35(1):27–41. doi:10.1007/s40266-017-0510-629350336
   PubMed Web of Science ®Google Scholar